SCHEMBL3283740

SCHEMBL3283740

O=C1Nc2ccc(F)cc2/C1=C/c1cc2cccccc-2c1

nearest known ligand 0.66

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ RPS6KA3 P51812 1/20 0.66
▸ FLT3 P36888 3/20 0.66
▸ MEN1 O00255 1/20 0.62
▸ KMT2A Q03164 1/20 0.62
▸ LRRK2 Q5S007 3/20 0.60
▸ RAF1 P04049 1/20 0.60
▸ KDR P35968 5/20 0.59
▸ CDK2 P24941 3/20 0.51
▸ CCNE1 P24864 2/20 0.51
▸ CCNE2 O96020 1/20 0.51
▸ ALK Q9UM73 1/20 0.51
▸ PARP1 P09874 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3283744 1.00 RPS6KA3 (0.66) RPS6KA3FLT3MEN1KMT2ALRRK2
SCHEMBL3283850 1.00 RPS6KA3 (0.66) RPS6KA3FLT3MEN1KMT2ALRRK2
SCHEMBL13080901 0.90 FLT3 (0.71) RPS6KA3FLT3MEN1KMT2ALRRK2
SCHEMBL3755027 0.90 FLT3 (0.71) RPS6KA3FLT3MEN1KMT2ALRRK2
SCHEMBL3755030 0.90 FLT3 (0.71) RPS6KA3FLT3MEN1KMT2ALRRK2
SCHEMBL3284863 0.86 KDR (0.63) RPS6KA3FLT3MEN1KMT2ALRRK2
SCHEMBL3283037 0.86 KDR (0.63) RPS6KA3FLT3MEN1KMT2ALRRK2
SCHEMBL3283034 0.86 KDR (0.63) RPS6KA3FLT3MEN1KMT2ALRRK2
SCHEMBL3284695 0.84 FLT3 (0.66) FLT3MEN1KMT2ALRRK2RAF1
SCHEMBL3284696 0.84 FLT3 (0.66) FLT3MEN1KMT2ALRRK2RAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1918277-B1 Azulene compounds IND TECH RES INST (TW) 2015-06-10 — — EP disclosed
EP-1918277-B1 Azulene compounds IND TECH RES INST (TW) 2015-06-10 — — EP disclosed
US-7714146-B2 Azulene-oxindole compounds as multiple-kinase inhibitors and useful as anticancer agents INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 2010-05-11 — — US disclosed
US-7714146-B2 Azulene-oxindole compounds as multiple-kinase inhibitors and useful as anticancer agents INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 2010-05-11 — — US disclosed
US-7714146-B2 Azulene-oxindole compounds as multiple-kinase inhibitors and useful as anticancer agents INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 2010-05-11 — — US disclosed
US-20080125590-A1 Azulene compounds INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 2008-05-29 — — US disclosed
US-20080125590-A1 Azulene compounds INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 2008-05-29 — — US disclosed
US-20080125590-A1 Azulene compounds INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 2008-05-29 — — US disclosed
EP-1918277-A2 Azulene compounds Industrial Technology Research Institute (TW) 2008-05-07 — — EP disclosed
EP-1918277-A2 Azulene compounds Industrial Technology Research Institute (TW) 2008-05-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080125590-A1 Azulene compounds AZI2, PRMT5, BRCA1 RPS6KA3 654/4885FLT3 796/4885MEN1 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback